Cargando…
Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer
Lung cancer remains the most frequently diagnosed cancer in the United States, excluding non-melanoma skin cancer. Non-small cell lung cancer (NSCLC) constitutes the majority (more than 80%) of lung cancer diagnoses. Systemic therapy, with either cytotoxic chemotherapy and/or targeted therapies, has...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117629/ https://www.ncbi.nlm.nih.gov/pubmed/21695100 http://dx.doi.org/10.4137/CMO.S5074 |
_version_ | 1782206348336824320 |
---|---|
author | Faller, Bryan A. Pandit, Trailokya N. |
author_facet | Faller, Bryan A. Pandit, Trailokya N. |
author_sort | Faller, Bryan A. |
collection | PubMed |
description | Lung cancer remains the most frequently diagnosed cancer in the United States, excluding non-melanoma skin cancer. Non-small cell lung cancer (NSCLC) constitutes the majority (more than 80%) of lung cancer diagnoses. Systemic therapy, with either cytotoxic chemotherapy and/or targeted therapies, has been established to provide benefit to patients with NSCLC in both the adjuvant and advanced disease settings. Vinorelbine, a semi-synthetic vinca-alkaloid has been extensively tested alone and in combination with other cytotoxic or targeted agents in the treatment of NSCLC. Its safety has been well established with neutropenia, anemia, nausea, and vomiting being the most frequently encountered toxicities. The data defining the risks and benefits of vinorelbine in the treatment of NSCLC will be summarized. |
format | Online Article Text |
id | pubmed-3117629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-31176292011-06-21 Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer Faller, Bryan A. Pandit, Trailokya N. Clin Med Insights Oncol Review Lung cancer remains the most frequently diagnosed cancer in the United States, excluding non-melanoma skin cancer. Non-small cell lung cancer (NSCLC) constitutes the majority (more than 80%) of lung cancer diagnoses. Systemic therapy, with either cytotoxic chemotherapy and/or targeted therapies, has been established to provide benefit to patients with NSCLC in both the adjuvant and advanced disease settings. Vinorelbine, a semi-synthetic vinca-alkaloid has been extensively tested alone and in combination with other cytotoxic or targeted agents in the treatment of NSCLC. Its safety has been well established with neutropenia, anemia, nausea, and vomiting being the most frequently encountered toxicities. The data defining the risks and benefits of vinorelbine in the treatment of NSCLC will be summarized. Libertas Academica 2011-05-10 /pmc/articles/PMC3117629/ /pubmed/21695100 http://dx.doi.org/10.4137/CMO.S5074 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
spellingShingle | Review Faller, Bryan A. Pandit, Trailokya N. Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer |
title | Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer |
title_full | Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer |
title_fullStr | Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer |
title_full_unstemmed | Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer |
title_short | Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer |
title_sort | safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117629/ https://www.ncbi.nlm.nih.gov/pubmed/21695100 http://dx.doi.org/10.4137/CMO.S5074 |
work_keys_str_mv | AT fallerbryana safetyandefficacyofvinorelbineinthetreatmentofnonsmallcelllungcancer AT pandittrailokyan safetyandefficacyofvinorelbineinthetreatmentofnonsmallcelllungcancer |